Company Description
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors.
It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology.
The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease.
Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF.
The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors.
It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology.
The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease.
Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF.
The company was founded in 2013 and is headquartered in Emeryville, California.
| Country | United States |
| IPO Date | Dec 11, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 147 |
| CEO | Dr. David H. Kirn M.D. |
Contact Details
Address: 5858 Horton Street EmeryVille, California United States | |
| Website | https://www.4dmoleculartherapeutics.com |
Stock Details
| Ticker Symbol | FDMT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001650648 |
| CUSIP Number | 35104E100 |
| ISIN Number | US35104E1001 |
| Employer ID | 47-3506994 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. David H. Kirn M.D. | Co-Founder, Chief Executive Officer & Director |
| Dr. Fariborz Kamal Ph.D. | President & Chief Operating Officer |
| Dr. Scott P. Bizily J.D., Ph.D. | Chief Legal Officer & Corporate Secretary |
| Dr. Alan H. Cohen FAAAAI, FAAP, FACAAI, FCCP, M.D. | Senior Vice President & Therapeutic Area Head of Pulmonology |
| Dr. An Song Ph.D. | Chief Development Officer |
| Dr. John F. Milligan Ph.D. | Executive Chairman |
| Dr. Noriyuki Kasahara M.D., Ph.D. | Chief Scientific Officer |
| Dr. Robert Y. Kim M.B.A., M.D. | Chief Medical Officer |
| Theresa Janke | Co-Founder & Chief of Staff |
| Uneek Mehra | Chief Financial & Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 11, 2024 | 8-K | Current Report |
| Dec 10, 2024 | 4 | Filing |
| Dec 06, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 25, 2024 | 3 | Filing |
| Nov 15, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 13, 2024 | 4 | Filing |